type here...
type here...
START FREE TRIAL

Healthcare

Technology & AIHealthcareM&AConsumer & RetailMiscellaneousEnergy

This Telehealth Stock Rally By RFK Jr. Looks Like Policy; It’s Actually A Margin SHIFT

Healthcare Ishan Majumdar -
Hims & Hers Health (NYSE:HIMS) did not report a surprise quarter, launch a blockbuster product, or raise guidance when the stock jumped after Robert...

Eli Lilly’s Foundayo & The GLP-1 Pivot From Innovation to Access Control!

Healthcare Ishan Majumdar -
Most coverage of Eli Lilly’s(NYSE:LLY) Foundayo launch has treated it like the next round in the company’s fight with Novo Nordisk. That is true,...
spot_imgspot_img

This Biotech Stock Already Has A Blockbuster; So Why Is It ACQUIRING Another Rare Disease Asset?

Healthcare Ishan M. -
There are biotech stories that look obvious, and then there are biotech stories that quietly change shape right in...

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Healthcare Ishan Majumdar -
Boston Scientific (NYSE:BSX) spent the weekend putting forward what looked, at first glance, like a clinically solid case for...

A First-In-Class Biotech Is Still Trading Below Its Strategic Value Today

Healthcare Ishan Majumdar -
A mid-cap biotech with the first approved therapy in a large, long-underfunded liver disease category is not supposed to...

Is Align A Classic Activist Win, Or A HARDER Consumer Story?

Healthcare Ishan Majumdar -
Align Technology (NASDAQ:ALGN) has become a useful test case for a very modern market question. What happens when Wall...

Qiagen Just Dropped Two Magic Words—And Wall Street Heard “Buyout”

Healthcare Ishan Majumdar -
Qiagen (NYSE:QGEN) just did the thing companies do right before Wall Street starts whispering louder. On March 2, CEO...

Is Merck’s HIV Win Really About Keytruda?

Healthcare Ishan Majumdar -
When Merck & Co. (NYSE:MRK) reported Phase 3 data showing its two-drug HIV regimen of doravirine and islatravir matched...
Load more

This Telehealth Stock Rally By RFK Jr. Looks Like Policy; It’s Actually A Margin SHIFT

Healthcare Ishan Majumdar -
Hims & Hers Health (NYSE:HIMS) did not report a surprise quarter, launch a blockbuster product, or raise guidance when...

Eli Lilly’s Foundayo & The GLP-1 Pivot From Innovation to Access Control!

Healthcare Ishan Majumdar -
Most coverage of Eli Lilly’s(NYSE:LLY) Foundayo launch has treated it like the next round in the company’s fight with...

This Biotech Stock Already Has A Blockbuster; So Why Is It ACQUIRING Another Rare Disease Asset?

Healthcare Ishan M. -
There are biotech stories that look obvious, and then there are biotech stories that quietly change shape right in...

This Medical Device Stock Just Got CRUSHED On One Hidden Number; Did Wall Street Misread It?

Healthcare Ishan Majumdar -
Boston Scientific (NYSE:BSX) spent the weekend putting forward what looked, at first glance, like a clinically solid case for...

A First-In-Class Biotech Is Still Trading Below Its Strategic Value Today

Healthcare Ishan Majumdar -
A mid-cap biotech with the first approved therapy in a large, long-underfunded liver disease category is not supposed to...

Is Align A Classic Activist Win, Or A HARDER Consumer Story?

Healthcare Ishan Majumdar -
Align Technology (NASDAQ:ALGN) has become a useful test case for a very modern market question. What happens when Wall...

Qiagen Just Dropped Two Magic Words—And Wall Street Heard “Buyout”

Healthcare Ishan Majumdar -
Qiagen (NYSE:QGEN) just did the thing companies do right before Wall Street starts whispering louder. On March 2, CEO...

Is Merck’s HIV Win Really About Keytruda?

Healthcare Ishan Majumdar -
When Merck & Co. (NYSE:MRK) reported Phase 3 data showing its two-drug HIV regimen of doravirine and islatravir matched...

Did Novo Nordisk’s Trial Miss Just Hand Lilly The Edge?

Healthcare Ishan Majumdar -
It has been a bruising few weeks for Novo Nordisk (NYSE:NVO). First came the clinical disappointment: CagriSema, the company’s...

Did Moderna’s Flu Rejection Signal A Deeper FDA SHIFT?

Healthcare Ishan Majumdar -
Moderna’s seasonal flu vaccine application was refused review by the FDA, triggering an immediate stock decline. The agency issued...

Hims & Hers Just Went Big on Cancer—But the DOJ Is Watching

Healthcare Ishan Majumdar -
Hims & Hers used the Super Bowl stage to push its latest offering: a $689 early cancer detection test....

Pfizer Takes On Eli Lilly & Novo: Who Gets OUTPLAYED in the Obesity Arms Race?

Healthcare Ishan Majumdar -
Pfizer just released mid-stage data from its Metsera-acquired obesity drug showing 12.3% weight loss at 28 weeks with monthly...
Load more

Baptista Research is a financial research house focused on the U.S. markets. We cover the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms.

Company

Headlines

Microsoft Earnings: Why Azure Growth Could Reprice The Entire Stock

0
Microsoft doesn’t need to beat earnings this quarter. It...

Tesla Heads Into Earnings With A Cleaner Setup Than The Reality Suggests!

0
Tesla heads into its Q1 2026 report with sentiment...

This Telehealth Stock Rally By RFK Jr. Looks Like Policy; It’s Actually A Margin SHIFT

0
Hims & Hers Health (NYSE:HIMS) did not report a...

Did Meta & Snap Just Hit An Attention LIMIT That Changes Ad Economics?

0
Meta Platforms (NASDAQ:META) and Snap Inc. (NYSE:SNAP) are often...

Newsletter

Get important news delivered directly to your inbox and stay connected!

Copyright © 2026 Baptista Research. All rights reserved.